Peptides and engineered T cell receptors targeting FANCI, RAD51, and PBK antigens and methods of use

JP2024526836A5Pending Publication Date: 2025-07-25BOARD OF RGT THE UNIV OF TEXAS SYST
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024503352
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-07-19
Filing Date
2022-07-18
Publication Date
2025-07-25

AI Technical Summary

Technical Problem

There is a need for engineered T-cell receptors (TCRs) that are specifically directed against cancer-specific antigens for effective cancer treatment, as existing TCRs may not adequately target tumor cells due to limitations in peptide major histocompatibility complex (pMHC) interactions.

Method used

Development of polypeptides and TCRs with antigen-binding variable regions that include CDR3 sequences with at least 80% sequence identity to specific amino acid sequences, enabling targeted recognition of cancer-specific peptides such as Fanci, RAD51, or PBK, and their use in engineered T cells for cancer therapy.

Benefits of technology

The engineered TCRs enhance the ability of T cells to recognize and destroy cancer cells by specifically binding to cancer-specific antigens, potentially improving treatment efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000093_0000
    Figure 00000093_0000
  • Figure 00000093_0001
    Figure 00000093_0001
  • Figure 00000093_0002
    Figure 00000093_0002
Patent Text Reader

Abstract

The present disclosure provides engineered T cell receptors (TCRs), cells that contain TCRs, and methods for making and using TCRs. The present disclosure relates to TCRs that specifically recognize epitopes derived from tumor antigens FANCI, RAD51, and PBK. Thus, aspects of the present disclosure relate to engineered T cell receptors (TCRs), nucleic acids that code TCRs, and cells that contain the nucleic acids and TCRs. Also provided are compositions that include the cells, nucleic acids, or engineered TCRs of the present disclosure, methods for making the cells, and methods for using aspects of the present disclosure for therapeutic treatment.
Need to check novelty before this filing date? Find Prior Art